Introduction: Acne vulgaris is a prevalent dermatological disorder that affects millions worldwide, causing both physical discomfort and psychological burden. Conventional therapies often provide limited benefit due to poor skin permeability and tolerability issues. Methods: This study covers indepth literature study (2000–2025) on Adapalene in acne treatment. Closely related 150 studies on innovative nanocarriers and the role of AI in Drug Delivery were included, while unrelated works were excluded. Results: Although adapalene demonstrates strong anti-acne activity, its limited membrane permeability and local dermatological adverse reactions restrict clinical effectiveness. Nanocarrier-based systems resolved these issues by enhancing drug penetration and controlled release, as evidenced by case studies and major clinical trials. ANN-assisted optimization further refined drug delivery, enabling more effective and personalized management of acne. Discussion: Adapalene is a promising therapeutic agent for acne vulgaris; however, its limited pharmacokinetic profile restricts its effectiveness. The integration of nanotechnology and AI-driven optimization could significantly improve its therapeutic potential, a concept further supported by findings from various clinical studies. Conclusion: Adapalene-loaded nanocarriers represent a promising approach for improving therapeutic outcomes in acne treatment. Integration of AI-based optimization with clinical validation highlights its translational potential, paving the way toward safer, more efficient, and patient-specific dermatological therapies.
Verma et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: